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Abstract
Background: Diabetic retinopathy is the most common cause of blindness in working-age adults. Characteristics of
patients with diabetes presenting to a retina subspecialty clinic have not been adequately studied, limiting our
ability to risk stratify patients with diabetic retinopathy. Our goal is to describe an innovative program that collects
structured, longitudinal data on patients with diabetes in a retina clinic, and identifies population characteristics to
define patient risk stratification.
Methods: Demographics, body-mass index, blood pressure, hemoglobin A1c, smoking history, diabetes type,
diabetes duration, kidney disease history, and diagnosis codes were collected on all patients with diabetes at the
Kellogg Eye Center retina clinic. A mixed effects negative binomial regression was then performed to assess visit
frequency as a function of these variables. Visit frequency was used as a marker for cost of care. A subgroup of
patients was surveyed about knowledge of diabetes management goals and barriers to better self-management.
Results: There were 2916 patients in the cohort with 1014 in the subgroup. The cohort was predominantly
Caucasian (74.5%), with a mean age of 64 years (range 13–99) and a relatively even distribution of sex (53.2% men).
The mean maximum hemoglobin A1c was 8.0% (range 4.3–15.7%), and 57.1% had a diagnosis of diabetic
retinopathy. Patients averaged 3.9 visits (range 1–27) during the 18-month study period. Blood pressure and
duration of diabetes were positively associated with visit frequency (p < 0.0001, p < 0.0001, respectively). Of the
surveyed patients, 87.6% knew their goal hemoglobin A1c, while only 45.9% identified the correct blood pressure
goal. The most common reported barrier to better self-management was “it’s just not working” (47.1%).
Conclusions: Implementation of this program enables the creation of a longitudinal dataset on patients with
diabetes. Resulting data can be used to improve quality of care provided to patients at a retina clinic. The findings
suggest considerable healthcare resources are being directed to a small patient population. This enhanced
understanding of characteristics of patients with diabetes will improve efforts to preserve vision and utilize health
system resources efficiently.
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Background
Diabetic retinopathy (DR) is one of the most common
complications of diabetes mellitus [1] and is the leading
cause of blindness in working-age adults in the world
[2], with the number of affected individuals worldwide
expected to increase from 126 million in 2010 to 191
million by 2030 [2]. In addition, DR represents a signifi-
cant financial burden to society. In the United States,
the direct medical costs alone for DR were estimated at
more than $490 million in 2004 [3]. This, however, is
likely an under-estimation of the current direct costs, as
treatment of DR has changed significantly since 2004
with the introduction of intravitreal anti-vascular endo-
thelial growth factor agents. Unfortunately, more recent
estimates of DR costs are not available. In addition, in-
direct costs, such as job absenteeism and burden on
family members, are not included. There is also little un-
derstanding of which patients are most likely to develop
vision-threatening DR and require treatment, versus
who will not. With dramatic projected increases in the
number of persons with diabetes and associated costs of
their care, it will be critical to improve the efficiency of
health care resource use in the future. In this report, we
describe a novel program designed to collect systemic
health data in the setting of an ophthalmology clinic,
with the goal of improving care and resource manage-
ment in the future.
Considerable research has elucidated the risk factors
for and the effect of interventions on the development
and progression of DR. Longer duration of diabetes mel-
litus, poor glycemic control as measured by hemoglobin
A1c (HbA1c), and higher blood pressures (BPs) are asso-
ciated with increased incidence and prevalence of DR
[4–8]. Increased HbA1c and longer diabetes duration, in
particular, are consistently shown to also be associated
with progression to more severe retinopathy [6, 8, 9].
Fortunately, aggressive control of both blood glucose
and BP significantly reduces the risk for development
and progression of DR [10–17]. Interestingly, the United
Kingdom Prospective Diabetes Study follow-up studies
in 2008 showed that the beneficial effects of intensive
glycemic control on any diabetes-related end point, micro-
vascular disease, myocardial infarction, and all-cause mor-
tality in patients with type 2 diabetes were sustained for
up to ten years after cessation of interventions while
similar benefits of BP control were lost at the ten-year
mark [11, 12].
Despite the clear importance of parameters such as
HbA1c, and BP in the prevention and treatment of DR, it
is not standard practice for ophthalmologists to actively
check HbA1c or BP during routine eye care visits, even if
these values are otherwise unavailable from the patient
record. Therefore, many ophthalmologists are unaware
of their patients’ overall diabetes management status.
This lack of awareness is surprising given the frequency
with which patients with retinopathy see ophthalmolo-
gists. Management of DR often involves intraocular pro-
cedures, frequently performed on a monthly basis,
which can put significant strain on the patient and fam-
ily, as well as health care resources. Yet, it is unclear
which patients will progress to requiring treatment, and
which will need aggressive management. Without
adequate data on systemic diabetes management param-
eters, ophthalmologists are unlikely to be able to develop
risk algorithms or to improve prognostic capability. The
purpose of this study is to report on the novel imple-
mentation of a sustainable program that combines
survey data, electronic health record (EHR) data, and
when otherwise unavailable, screening data obtained
during routine ophthalmology clinic visits, and to report
on initial findings from analysis of this data. A more
comprehensive understanding of patients’ diabetes status
will allow ophthalmologists to better risk stratify patients
and tailor care accordingly, leading to a more efficient
use of health care resources. In addition, a more thor-
ough understanding of DR in the context of systemic
diabetes care will allow for future quality benchmarking
and improvement.
There are few reports describing systemic characteris-
tics of patients with diabetes presenting to a retina or
eye clinic. One such study, conducted in 1998, evaluated
118 patients with diabetes who newly presented to an
inner city public eye hospital in Los Angeles. The patient
population consisted predominately of minority groups
(55% Hispanic and 43% African American) and individ-
uals of low socioeconomic status [18]. This study did
not examine HbA1c or BP. These data are unlikely to
represent diabetic populations today, since the manage-
ment of systemic diabetes and DR have changed signifi-
cantly in the past two decades. In addition, the relatively
small sample size and study location limit potential
extrapolation.
To our knowledge, a program designed to routinely
collect systemic health data on patients with diabetes
presenting to a retina clinic has not been previously
implemented.
Methods
The Comprehensive Diabetic Retinopathy Program
(CDRP) was developed by the faculty from the Michigan
Medicine Ophthalmology and Visual Sciences retina
clinic, the Metabolism, Endocrinology and Diabetes
Clinic and the University of Michigan Brehm Diabetes
Center, in conjunction with current American Diabetes
Association guidelines. CDRP was developed as a quality
improvement project, and was thus IRB-exempt. The goal
of the program was to incorporate data acquisition, in-
cluding point-of-care HbA1c testing and BP measurements
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into normal retina clinic workflow, in the hopes that fu-
ture analysis of this data will impact patient management
decisions. In addition, all relevant diabetes information is
stored in a structured manner, such that it is easily ex-
tracted for analysis, while also being available to the phys-
ician as part of an easily accessible “form” linked to each
individual patient encounter in the EHR.
Demographics, body mass index (BMI), BP, HbA1c,
smoking history, diabetes type, diabetes duration, kidney
disease history based on both self-report and microalbu-
minuria (≥ 30 μg albumin/mg creatinine), and diagnosis
codes were collected on all patients with diabetes pre-
senting to the Kellogg Eye Center retina clinic for new
patient visits and return visits from July 1, 2016 to De-
cember 30, 2017 via survey questions and information
available in the EHR. Microalbumin was chosen as a
marker because it is a screening test shown to be highly
sensitive for early diabetic nephropathy [19], and because
it is used as a marker by the diabetes quality improvement
group at the institution. Though values were recorded for
each patient at each encounter, point-of-care HbA1c and
BP were only checked in the clinic if no values were
already present in the EHR from the previous six months.
For patients who had multiple visits and correspondingly
multiple measures, the maximum value has been used for
the analysis. The number of visits is calculated only for
those patients who presented to the clinic for at least 12
months. To analyze visit frequency, we ran a mixed effects
negative binomial regression with the number of visits as
an outcome and age, sex, race, maximum HbA1c, presence
or absence of DR diagnosis codes, the interaction term be-
tween maximum HbA1c and DR diagnosis codes, diabetes
type, duration of diabetes for ≥10 years, kidney disease his-
tory, maximum systolic blood pressure (SBP), maximum
diastolic blood pressure (DBP) as fixed effects and pa-
tients’ providers as a random effect. Mixed effects negative
binomial regression as well as frequencies, mean, standard
deviations and ranges have been calculated using SAS
(version 9.4, SAS Institute, Triangle Park, NC, USA).
Ophthalmic technicians obtained point-of-care HbA1c
and BP measurements on all patients identified as hav-
ing diabetes who did not have values from within 6
months in the EHR, regardless of whether or not they
were being seen for diabetic retinopathy. In addition,
these patients were asked about their knowledge of any
history of kidney disease, and whether they had diabetes
for over 10 years. Other information was obtained from
pre-existing data in the EHR.
A subgroup of patients with 2 or more of the following
factors, determined “high risk” for complications by en-
docrinologists based on previously published data [6,
20–22] and clinical experience, was targeted for add-
itional data collection and analysis: HbA1c > 9% or BP >
140/90 mmHg in the last six months, history of kidney
disease based on either self-report or microalbuminuria,
diabetes duration ≥10 years. From July 1, 2016 to July 1,
2017, subgroup patients were asked to complete a
three-question multiple-choice survey assessing know-
ledge of diabetes management goals. During the entire
study period, subgroup patients were also verbally
surveyed about their perceived barriers to better control
of their diabetes. In addition, they were provided litera-
ture on other community resources, such as smoking
cessation and diabetes education classes. Technicians
conducting these surveys and providing this additional
information had completed 10 h of standard patient dia-
betes education classes and undergone a two-hour train-
ing session with an endocrinologist to ensure their
comfort with the material being discussed.
Results
Data were recorded from 2916 unique patients with
8470 encounters (Table 1). The following was the racial
composition of the cohort: 74.5% white/Caucasian,
14.8% black/African American, 4.6% Asian, and 6.2% un-
known/other/mixed. 64.6% of patients had type 2 dia-
betes, and there was a relatively even distribution of sex
(46.8% women and 53.2% men). The mean age was 64
years (range 13–99), and the cohort was predominantly
obese, with mean maximum BMI 33.5 kg/m2 (SD = 7.96).
Mean maximum HbA1c was 8.0% (range 4.3–15.7%),
with the mode of the distribution at the value of 7.2%
with a tail toward larger values; 66.2% of patients had
HbA1c values > 7 and 22.6% of patients > 9%. Although
data were acquired on every patient with diabetes pre-
senting to the retina clinic, only 57.1% (1664) had any
encounter diagnosis of DR; other patients were being
seen, presumably, for other problems. The average num-
ber of visits was 3.9 in an 18-month period (range 1–27
visits).
A mixed effects negative binomial regression model
identified variables associated with number of visits to
the retina clinic (Table 2). Only patients who pre-
sented with the potential for at least 12 months of
follow up were included in the analysis of total num-
ber of visits. In our sample, missing HbA1c and BP
values were more common in patients without a diag-
nosis of DR (of any kind). To control for this
non-random factor of missing values, we included an
indicator for presence of DR in our model. Random
effect was also statistically significant (p < 0.001). The
interaction term between patient’s maximum HbA1c
and DR was statistically significant (p = 0.006). Among
patients with a diagnosis of DR, HbA1c was not sta-
tistically significantly associated with the number of
visits while controlling for other covariates. Other
variables that were positively associated with visit fre-
quency include Caucasian race versus Asian (p =
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0.048), unknown type of diabetes versus type 2 (<
0.0001), SBP (< 0.0001), DBP (< 0.0001), and a dur-
ation of diabetes ≥10 years. Type 1 diabetes vs. type 2
(< 0.0001) was negatively associated with more fre-
quent follow-up while holding other covariates con-
stant. The magnitude of the scaled Pearson statistic
(0.95) indicates that there was no over-dispersion in
our model.
Responses from the survey on diabetes management
goals, asked only of patients with two or more risk charac-
teristics for the first 12months of the program, are pre-
sented in Table 3. While 87.6% of patients surveyed were
Table 1 Characteristics of Patients with Diabetes Presenting to a Retina Clinic
Entire cohort Subsample: risk score≧ 2
N = 2916 N = 1014
N or Mean % or SD Min Max N or Mean % or SD Min Max
Patient age Mean (SD) 64.05 14.29 13 99 62.79 13.89 17 98
Race N(%)
Asian 134 4.60 39 3.85
Black, African American 431 14.78 198 19.53
White or Caucasian 2171 74.45 715 70.51
Unknown/other/mixed 180 6.17 62 6.11
Sex N(%)
Female 1365 46.81 467 46.06
Male 1551 53.19 547 53.94
Ever smoked N (%)
Yes 1287 44.14 415 40.93
No/unknown 1629 55.86 599 59.07
Diabetic retinopathy N (%)
Yes 1664 57.06 806 79.49
No 1252 42.94 208 20.51
Diabetes type N(%)
Type 1 356 12.21 143 14.10
Type 2 1883 64.57 736 72.58
Undefined 677 23.22 135 13.31
Maximum microalbumin N(%)
< 30 239 8.20 96 9.47
≧30 186 6.38 159 15.68
Unknown 2491 85.43 759 74.85
History of kidney diagnosis N(%)
Yes 509 17.46 436 43.00
No/unknown 2407 82.54 578 57.00
Duration of diabetes ≧10 years
Yes 1404 48.15 885 87.28
No 1512 51.85 129 12.72
Max patient’s BMI Mean (SD 33.46 7.96 17 81 34.02 8.39 17 81
Maximum systolic blood pressure Mean (SD) 141.91 22.86 80 237 152.71 22.7 87 237
Maximum diastolic blood pressure Mean (SD) 73.73 11.53 40 123 77.19 11.83 42 118
Maximum HbA1c Mean (SD) 8.01 1.80 4.30 15.70 8.68 2.01 4.70 15.70
Patient’s number of visits Mean (SD)a 3.91 3.70 1 27 4.85 4.11 1 25
aFor the number of visits outcome a subcohort of patients who presented with at least 12 months of potential follow up has been evaluated (N = 1504 for the
whole cohort; N = 634 for the subgroup of patients with risk score ≥ 2)
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aware of their goal HbA1c, only 45.9% of patients knew the
correct BP goal, consistent with findings by Duncan et al.
[23].
Patients (N = 1014) with two or more risk characteris-
tics who were willing to extend their clinic visit to dis-
cuss available diabetes-related resources were also asked
about their own perceptions of barriers to better
self-management of diabetes (Table 4). Patients were
allowed to choose multiple responses to this question.
The most commonly reported barrier was “it’s just not
working”, reported by 47.1% of patients who answered
the queries (N = 240).
Discussion
Implementation of the CDRP allowed the creation of a
longitudinal dataset on patients with diabetes presenting
to a retina clinic. In addition, data gathered is stored in a
Table 2 Negative binomial mixeda effects regression: Association between number of visits and patient characteristics
Cohort: visited the clinic for at least 12 months
n = 963
Effect Estimate Standard Error t Value Pr > |t|
Age 0.00007 0.002 0.04 0.969
Female (ref = Male) 0.03 0.04 0.75 0.454
Race
Black or African American (ref = Asian) −0.03 0.11 −0.28 0.776
Unknown/other/mixed (ref = Asian) 0.03 0.13 0.22 0.826
White or Caucasian (ref = Asian)b 0.20 0.10 1.98 0.048
Diabetes type
Type 1 (ref = Type 2)b −0.40 0.08 −5.26 <.0001
Undefined (ref = Type 2)b 0.21 0.06 3.28 0.001
Duration of diabetes ≧10 years (ref < 10 years)b 0.18 0.05 3.56 0.0004
History of kidney diagnosis Yes (ref = No) 0.08 0.05 1.74 0.082
Maximum systolic blood pressure (scaled by 10)b 0.05 0.01 4.38 <.0001
Maximum diastolic blood pressure (scaled by 10)b 0.16 0.03 6.00 <.0001
Maximum HbA1c
b −0.08 0.03 −2.52 0.012
Has Diabetic Retinopathy (ref = no) −0.20 0.26 −0.76 0.446
Interaction between maximum HbA1c and DR
b 0.09 0.03 2.75 0.006
aPatients’ providers were modeled as a random effect to set apart characteristics attributed to providers rather than to patients
bDenotes statistically significant effects associated with the number of visits at alpha = .05
Table 3 Diabetes Goals Survey Results (July 1, 2016-July 1, 2017)
Within the Subsample: risk score > 2
n = 418 (patients who answered)
Survey Questions and Responses n %
HbA1c goal (%):
< 7.0 (correct) 366 87.56
7.0–9.0 32 7.66
> 9.0 0 0.00
No recommendation 3 0.72
No/unclear answer 17 4.07
Blood Pressure goal (mmHg)
< 140/90 (correct) 192 45.93
< 120/80 201 48.09
< 160/100 8 1.91
No recommendation 2 0.48
No/unclear answer 15 3.59
Table 4 Patient Self-Reported Barriers to Better Control of Their
Diabetes
Within the Subsample: risk score > 2
n = 240 (patients who answered)
Barriersa n %
It’s just not working 113 47.08
No barriers 67 27.92
Depression/anxiety 19 7.92
Forgetting medication 18 7.50
Cost of supplies 5 2.08
Transportation 5 2.08
To get supplies 5 2.08
Getting an appointment 4 1.67
Medication cost 2 0.83
To get medications 2 0.83
aPatients were allowed to specify more than 1 barrier
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structured format as part of the EHR, allowing access by
the treating physician and future analysis in an
encounter-specific way. To the best of our knowledge,
this is the first structured quality improvement program
that combines systemic data from the EHR and queries
from patients in a retina clinic. The CDRP is unique not
only because of its novelty, but because data acquisition
was incorporated into the routine workflow of a busy
retina clinic, with minimal disruption to care and in an
easily accessible format, allowing for future adoption
and expansion to other practices. The program, which is
the first to longitudinally combine systemic data with
ophthalmic findings and management plans, enables the
identification of metabolic and patient-specific personal
attributes that influence the risk of complications.
The demographics are as expected for this cohort that
presents to a large academic medical center in a rela-
tively affluent medium-sized metropolitan area. Interest-
ingly, more than 40% of patients with diabetes seeking
retina care do not have a diagnosis of DR based on en-
counter diagnosis codes, implying that their clinic visits
were either for retinopathy screening or for other diag-
noses. Additionally, only a small fraction reported a his-
tory of kidney disease or had microalbuminuria.
However, given that this data relied in large part on pa-
tient reports, it is likely that this is underreported. The
overall cohort has low average maximum HbA1c, rela-
tively well-controlled BPs, and low mean number of
visits; however, the large ranges and distributions of
maximum HbA1c values (4.3–15.7%, and 77.38% of pa-
tients have maximum HbA1c ≤ 9%), maximum SBP (80–
237 mmHg) and DBP (40–123 mmHg), and number of
visits over 18 months (1 to 27) suggest that significant
healthcare resources are being devoted to a relatively
small number of patients. In fact, only 35.58% of patients
with DR (N = 1664) had any invasive treatment (includ-
ing intravitreal injections and laser) during the
18-month study period (implying that others had mild
or stable disease). These data show that even in a popu-
lation skewed towards higher rates of DR and DR com-
plications (as all patients in the cohort are persons with
diabetes presenting to a retina clinic), a small number of
patients require a large amount of health care resources.
Our hypothesis that the distribution of clinical resources
is skewed towards a small number of patients is further
supported by the fact that increasing numbers of visits
are correlated with duration of diabetes ≥10 years, and
higher SBP and DBP. This is, to our knowledge, the first
report to link systemic diabetes parameters to outcomes
such as frequency of ophthalmology follow up, which is
an important marker of cost of care. Furthermore, data
from the CDRP were recently analyzed to show that BP
is also significantly associated with receiving an intravit-
real injection in patients with diabetes whereas HbA1c is
not [24]. This is also a previously unreported finding,
and could have significant implications for ophthalmolo-
gists counseling patients with DR, and for the manage-
ment of their retinal disease. Programs like CDRP may
be valuable to identify which individuals require the
most intensive treatment, and what factors led to their
inclusion in that group.
Patients’ awareness of diabetes management goals was
very good overall, with more than 87% of patients sur-
veyed knowing their HbA1c goal. Aiello and colleagues
recently concluded that personalized risk assessment
and education during ophthalmology visits did not im-
prove glycemic control [25]. In that study, patients were
provided details on risk assessment and scripted educa-
tion by an ophthalmologist. Our findings suggest an
explanation--that patients are already aware of their goal
glycemic control, and reminders regarding this are likely
unproductive.
In contrast, less than 46% of patients surveyed knew
their BP goal, with approximately 48% overall overesti-
mating the recommended degree of BP control. This
data demonstrates that there is a disconnect between pa-
tients’ knowledge of appropriate HbA1c and BP goals
and their ability to achieve them, a finding corroborated
in much of the diabetes education literature [25–28].
A study conducted in 2017 showed that a greater level
of perceived barriers to diabetes self-management is as-
sociated with close to 2.5 times greater odds of both
having any DR and having severe DR [29]. Analysis of
patients’ barriers to better management of their diabetes
in our study highlights the difficulty associated with
helping patients improve their diabetes management.
The most common barrier reported by patients in the
subgroup was that their efforts in self-management were
“just not working,” (47.1%) followed by “no barriers”
(27.9%). “Depression/anxiety” (7.9%) and “forgetting to
take medication” (7.5%) were less prevalent barriers, but
they are still important issues for caregivers to address.
A recent study showed divergent perceptions of barriers
to DR screening exams between providers and patients;
financial burdens and depression were most commonly
reported by patients as barriers to receiving screening,
whereas providers did not rate these barriers as import-
ant [30]. It is possible that similar discrepancies between
patient and physician perceptions of barriers to better
self-management exist in the management of diabetes
and its complications. As such, a more thorough under-
standing of perceived difficulties to self-management
may be a key component to achieving better systemic
disease control and may have potential long-term bene-
fits to patients and health system resources.
A notable strength of this study is the large patient co-
hort. Continued analysis of the data has already identi-
fied possible risk factors contributing to the need for
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intensive treatment and possibility of vision loss [24].
With continued data collection and analysis, CDRP will
also allow for development of benchmarks to determine
quality of care. Future development of a “risk score”
could lead to better prognostication and allocation of
health system resources.
A limitation of this study is that as a retrospective ana-
lysis it is subject to biases, such as the inability to con-
trol for confounding factors not available from the
patients’ EHR or surveys. Both assessment of baseline
parameters and acquisition of survey data regarding pa-
tient barriers and knowledge of diabetes management
goals depended on patients’ willingness to either get
testing not usually done in an eye care setting (point of
care HbA1c) or to spend extra time during their clinic
appointment to provide this information (the barriers
and diabetes goals surveys), which may cause selection
bias in our analysis. Some of the data, most notably
questions on history of kidney disease and duration of
diabetes, were also subject to recall bias. Finally, patients
may have reasons to avoid honestly reporting informa-
tion, such as smoking status. The program’s ongoing na-
ture, though, allows for adjustment to workflow and
data collection techniques. Recent changes in data col-
lection involve querying patients during their electronic
check-in procedure, which reduces respondent burden
and likely will increase response rate, as patients will no
longer be required to prolong their clinic visit in order
to provide information.
Conclusions
Approximately 15–17% of blindness in the developed
areas of the Americas and Europe can be attributed to
DR [2]. Not only is DR a major cause of visual decline,
but it also represents a significant financial burden to so-
ciety both in health care costs and disability implica-
tions. These costs are only expected to rise in the near
future. As such, programs like CDRP, which provide a
better understanding of the characteristics of patients
with diabetic eye disease, are essential to improving our
ability to preserve visual function and to limiting strain
on health system resources. This report describes the
population of patients with diabetes presenting to a large
academic retina practice and demonstrates how struc-
tured systemic data can be collected during routine eye
care visits as well as the potential value—both to the pa-
tient and the health care system--of analyzing this data.
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